CA3015430A1 - Radiolabeled macrocyclic egfr inhibitor - Google Patents

Radiolabeled macrocyclic egfr inhibitor Download PDF

Info

Publication number
CA3015430A1
CA3015430A1 CA3015430A CA3015430A CA3015430A1 CA 3015430 A1 CA3015430 A1 CA 3015430A1 CA 3015430 A CA3015430 A CA 3015430A CA 3015430 A CA3015430 A CA 3015430A CA 3015430 A1 CA3015430 A1 CA 3015430A1
Authority
CA
Canada
Prior art keywords
compound
egfr
formula
radiolabeled
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3015430A
Other languages
English (en)
French (fr)
Inventor
Jan Marie Cyriel Jozef Hoflack
Cyril BERTHET
Petra Marcella Francoise Blom
Johnny VERCOUILLIE
Caroline ROBIC
Sarah Catoen
Gilles Viot
Jean-Bernard Deloye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncodesign Precision Medicine SA
Original Assignee
ONCODESIGN SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ONCODESIGN SA filed Critical ONCODESIGN SA
Publication of CA3015430A1 publication Critical patent/CA3015430A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3015430A 2016-02-29 2017-02-28 Radiolabeled macrocyclic egfr inhibitor Pending CA3015430A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16157885.1 2016-02-29
EP16157885 2016-02-29
PCT/EP2017/054611 WO2017148925A1 (en) 2016-02-29 2017-02-28 Radiolabeled macrocyclic egfr inhibitor

Publications (1)

Publication Number Publication Date
CA3015430A1 true CA3015430A1 (en) 2017-09-08

Family

ID=55446700

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3015430A Pending CA3015430A1 (en) 2016-02-29 2017-02-28 Radiolabeled macrocyclic egfr inhibitor

Country Status (10)

Country Link
US (1) US10716869B2 (enExample)
EP (1) EP3423113B1 (enExample)
JP (1) JP6913101B2 (enExample)
AU (1) AU2017226878B2 (enExample)
CA (1) CA3015430A1 (enExample)
DK (1) DK3423113T3 (enExample)
ES (1) ES2833959T3 (enExample)
IL (1) IL261274B (enExample)
PT (1) PT3423113T (enExample)
WO (1) WO2017148925A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7262922B2 (ja) * 2017-12-06 2023-04-24 キヤノンメディカルシステムズ株式会社 タンパク質をイメージングする方法
WO2021055814A1 (en) * 2019-09-18 2021-03-25 The Regents Of The University Of California Positron emission tomography guided delivery of mitochondral complex i inhibitors
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
GB202108605D0 (en) * 2021-06-16 2021-07-28 Ge Healthcare Uk Ltd Effect of water content

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
JO2785B1 (en) 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
EP2951171A1 (en) 2013-02-01 2015-12-09 Boehringer Ingelheim International GmbH Radiolabeled quinazoline derivatives

Also Published As

Publication number Publication date
IL261274A (en) 2018-10-31
JP6913101B2 (ja) 2021-08-04
WO2017148925A1 (en) 2017-09-08
AU2017226878B2 (en) 2020-07-23
EP3423113B1 (en) 2020-09-02
JP2019507155A (ja) 2019-03-14
DK3423113T3 (da) 2020-11-30
US20190054197A1 (en) 2019-02-21
EP3423113A1 (en) 2019-01-09
AU2017226878A1 (en) 2018-09-27
IL261274B (en) 2020-05-31
US10716869B2 (en) 2020-07-21
ES2833959T3 (es) 2021-06-16
PT3423113T (pt) 2020-12-10

Similar Documents

Publication Publication Date Title
Slobbe et al. Development of [18F] afatinib as new TKI-PET tracer for EGFR positive tumors
Slobbe et al. A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C] erlotinib and [18F] afatinib in lung cancer-bearing mice
AU2017200934A1 (en) Compositions, methods, and systems for the synthesis and use of imaging agents
AU2017226878B2 (en) Radiolabeled macrocyclic EGFR inhibitor
JP6987840B2 (ja) Ｉｄｏ１酵素イメージングのための放射性リガンド
US20100226853A1 (en) Fluorine-18 derivatives of dasatinib and uses thereof
US20110097268A1 (en) Radiohaloimatinibs and methods of their synthesis and use in pet imaging of cancers
Rizzo-Padoin et al. [18F] MEL050 as a melanin-targeted PET tracer: fully automated radiosynthesis and comparison to 18F-FDG for the detection of pigmented melanoma in mice primary subcutaneous tumors and pulmonary metastases
US10039844B2 (en) Imaging tumor glycolysis by non-invasive measurement of pyruvate kinase M2
AU2024343052A1 (en) Radiopharmaceutical
US20150368230A1 (en) Radiolabeled quinazoline derivatives
JPWO2020017557A1 (ja) 新規化合物、および、その利用
Goggi et al. Identifying nonsmall‐cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging
JP2019043882A (ja) 代替抗癌剤の治療効果予測剤
EP3111960B1 (en) Nuclear medicine diagnostic imaging agent
JP6709552B2 (ja) 核医学画像診断薬
US12138320B2 (en) Composition and methods for tumor imaging and treatment
US20190023664A1 (en) Radiolabeled erlotinib analogs and uses thereof
JP2019064987A (ja) Ｂｃｒ−Ａｂｌタンパク質イメージング用分子プローブ
KR20180083812A (ko) 악성 흑색종 진단용 방사성 화합물 및 그의 용도
JP7024960B2 (ja) Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ
Mallik et al. [18F] F-ERi PET: a non-steroidal 18F-labeled lasofoxifene radiotracer for imaging the estrogen receptor
JP6739987B2 (ja) 核医学画像診断薬
CN118994151A (zh) 结合sigma-2受体的咪唑并吡啶酮类化合物、其制备方法和应用
Hicks et al. www. mdpi. com/journal/molecules

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220224

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250815

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250903

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251028

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107